Prenaital ApS has filed a patent for technology that may identify risks of spontaneous pre-term birth. Spontaneous preterm birth (sPTB) is usually defined as birth occurring before 37 weeks of gestation. The invention relates to a method for predicting potential preterm birth from medical scan data, which may be used in practice by medical professionals for risk analysis and prognosis of potential pathologies.
Chengdu Kanghong Pharmaceutical Co. Ltd. has disclosed leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of cancer, type 1 diabetes, glaucoma, inflammatory bowel disease, multiple sclerosis, neurodegeneration, psoriasis and rheumatoid arthritis, among others.
Beijing Tide Pharmaceutical Co. Ltd. has patented new cathepsin C (dipeptidyl peptidase I) inhibitors reported to be useful for the treatment of bronchiectasis.
Acerand Therapeutics (Hong Kong) Ltd. has divulged new cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of cancer.
Bio-Thera Solutions Ltd. has synthesized new antibody-drug conjugates comprising trastuzumab targeting HER2 (erbB2) covalently linked to exatecan through a linker reported to be useful for the treatment of cancer, inflammation, autoimmune disorders and infections.
Centre Hospitalier Regional Universitaire de Lille has patented new 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Sunshine Lake Pharma Co. Ltd. has patented new PKMYT1 inhibitors reported to be useful for the treatment of cancer, psoriasis and rheumatoid arthritis.
Beyang Therapeutics Co. Ltd. has divulged salts of vascular endothelial growth factor receptor (VEGFR) inhibitors reported to be useful for the treatment of cancer, fibrosis, autoimmune, inflammatory, neurodegeneration, cardiovascular, metabolic and eye disorders.
Shanghai Qingrun Pharmaceutical Technology Co. Ltd. has discovered new GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.
RSS
